Arca
Skip to content

Major depressive disorder

Drug research and approvals for major depressive disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 476 studies of major depressive disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 62 drug trials for it since 2013, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 476
  • Trials authorized in Canada: 62
  • FDA orphan approvals: 0
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 476 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 62; search them all in Canada trials
Sep 28, 2026A phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study with an open-label treatment period to evaluate the efficacy and…AGN-151607-DP (GEMIBOTULINUMTOXINA)AbbViePending
Sep 10, 2026A comparative analysis of the pharmacokinetics of oral and sublingual ketamine as adjunctive therapies in major depressive disorderKETAMINEDR. ROHIT LODHIPending
Sep 8, 2026A phase 3, multicenter, randomized, double-blind, parallel-arm study to investigate the efficacy and safety of adjunctive treatment with brenipatide in…BRENIPATIDE (LY3537031)Eli LillyOngoing
Jun 11, 2026A phase 3, multicenter, randomized, double-blind, parallel-arm study to investigate the efficacy and safety of adjunctive treatment with brenipatide in…BRENIPATIDE (LY3537031)Eli LillyOngoing
Jun 11, 2026Optimizing the synergy between behavioural activation therapy and intravenous ketamine for treatment resistant depressionKETAMINEUNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCHPending
May 29, 2026A multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy and safety of seltorexant as monotherapy in adult and elderly…SELTOREXANT (JNJ-42847922)Johnson & JohnsonOngoing
Nov 26, 2025Psilocybin-assisted psychotherapy for major depressive disorder in women with a history of childhood maltreatment: a pilot trialPSILOCYBIN (PEX010)DR. ELISA BRIETZKEOngoing
Nov 6, 2025Sustained mood improvement with laughing gas exposure: a randomized controlled double-blind trialNITROUS OXIDE / MIDAZOLAMWOMENS COLLEGE HOSPITALPending
Sep 26, 202518f]bcpp-ef pet imaging of mitochondrial complex i in major depressive disorder, treatment-resistant major depressive disorder, and long covid (pasc)[18F]BCPP-EFCENTRE FOR ADDICTION AND MENTAL HEALTHOngoing
Aug 19, 2025Two-week, open-label, exploratory neuroimaging study evaluating the effect of dextromethorphan-hbr bupropion-hcl on striatal reactivity during reward…DEXTROMETHORPHAN-BUPROPIONBRAIN AND COGNITION DISCOVERY FOUNDATIONPending

Medicines Authorised in the EU

Newest first

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.